nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimethoprim—TYMS—urinary bladder cancer	0.4	1	CbGaD
Trimethoprim—TYMS—Gemcitabine—urinary bladder cancer	0.109	0.249	CbGbCtD
Trimethoprim—TYMS—Fluorouracil—urinary bladder cancer	0.0929	0.213	CbGbCtD
Trimethoprim—DHFR—Methotrexate—urinary bladder cancer	0.0735	0.169	CbGbCtD
Trimethoprim—TYMS—Methotrexate—urinary bladder cancer	0.0512	0.118	CbGbCtD
Trimethoprim—ABCB1—Mitomycin—urinary bladder cancer	0.029	0.0665	CbGbCtD
Trimethoprim—CYP3A4—Thiotepa—urinary bladder cancer	0.0132	0.0302	CbGbCtD
Trimethoprim—CYP2C8—Fluorouracil—urinary bladder cancer	0.0105	0.0242	CbGbCtD
Trimethoprim—CYP2C8—Etoposide—urinary bladder cancer	0.0088	0.0202	CbGbCtD
Trimethoprim—ABCB1—Gemcitabine—urinary bladder cancer	0.00834	0.0191	CbGbCtD
Trimethoprim—CYP2C9—Fluorouracil—urinary bladder cancer	0.00735	0.0169	CbGbCtD
Trimethoprim—CYP2C9—Cisplatin—urinary bladder cancer	0.00625	0.0143	CbGbCtD
Trimethoprim—ABCB1—Cisplatin—urinary bladder cancer	0.00606	0.0139	CbGbCtD
Trimethoprim—ABCB1—Etoposide—urinary bladder cancer	0.00596	0.0137	CbGbCtD
Trimethoprim—ABCB1—Doxorubicin—urinary bladder cancer	0.00406	0.00932	CbGbCtD
Trimethoprim—ABCB1—Methotrexate—urinary bladder cancer	0.00394	0.00903	CbGbCtD
Trimethoprim—CYP3A4—Etoposide—urinary bladder cancer	0.00357	0.00819	CbGbCtD
Trimethoprim—CYP3A4—Doxorubicin—urinary bladder cancer	0.00243	0.00559	CbGbCtD
Trimethoprim—CYP2C9—urine—urinary bladder cancer	0.00175	0.0976	CbGeAlD
Trimethoprim—TYMS—prostate gland—urinary bladder cancer	0.00144	0.0803	CbGeAlD
Trimethoprim—DHFR—prostate gland—urinary bladder cancer	0.00142	0.0795	CbGeAlD
Trimethoprim—CYP3A4—urine—urinary bladder cancer	0.00133	0.0744	CbGeAlD
Trimethoprim—DHFR—seminal vesicle—urinary bladder cancer	0.0012	0.0672	CbGeAlD
Trimethoprim—TYMS—smooth muscle tissue—urinary bladder cancer	0.00102	0.0568	CbGeAlD
Trimethoprim—TYMS—Podofilox—Etoposide—urinary bladder cancer	0.000987	0.713	CbGdCrCtD
Trimethoprim—DHFR—renal system—urinary bladder cancer	0.00097	0.0542	CbGeAlD
Trimethoprim—DHFR—urethra—urinary bladder cancer	0.000953	0.0532	CbGeAlD
Trimethoprim—TYMS—female reproductive system—urinary bladder cancer	0.000784	0.0438	CbGeAlD
Trimethoprim—DHFR—female reproductive system—urinary bladder cancer	0.000777	0.0434	CbGeAlD
Trimethoprim—TYMS—vagina—urinary bladder cancer	0.000709	0.0396	CbGeAlD
Trimethoprim—DHFR—vagina—urinary bladder cancer	0.000702	0.0392	CbGeAlD
Trimethoprim—CYP2C8—renal system—urinary bladder cancer	0.000481	0.0269	CbGeAlD
Trimethoprim—TYMS—lymph node—urinary bladder cancer	0.000459	0.0256	CbGeAlD
Trimethoprim—DHFR—lymph node—urinary bladder cancer	0.000454	0.0254	CbGeAlD
Trimethoprim—TYMS—Azacitidine—Gemcitabine—urinary bladder cancer	0.000398	0.287	CbGdCrCtD
Trimethoprim—CYP2C8—female reproductive system—urinary bladder cancer	0.000386	0.0215	CbGeAlD
Trimethoprim—CYP2C8—vagina—urinary bladder cancer	0.000349	0.0195	CbGeAlD
Trimethoprim—CYP2C9—female reproductive system—urinary bladder cancer	0.000342	0.0191	CbGeAlD
Trimethoprim—ABCB1—prostate gland—urinary bladder cancer	0.000339	0.0189	CbGeAlD
Trimethoprim—CYP3A4—renal system—urinary bladder cancer	0.000326	0.0182	CbGeAlD
Trimethoprim—ABCB1—seminal vesicle—urinary bladder cancer	0.000286	0.016	CbGeAlD
Trimethoprim—CYP3A4—female reproductive system—urinary bladder cancer	0.000261	0.0146	CbGeAlD
Trimethoprim—ABCB1—epithelium—urinary bladder cancer	0.000249	0.0139	CbGeAlD
Trimethoprim—ABCB1—renal system—urinary bladder cancer	0.000231	0.0129	CbGeAlD
Trimethoprim—ABCB1—urethra—urinary bladder cancer	0.000227	0.0127	CbGeAlD
Trimethoprim—ABCB1—female reproductive system—urinary bladder cancer	0.000185	0.0103	CbGeAlD
Trimethoprim—ABCB1—vagina—urinary bladder cancer	0.000167	0.00934	CbGeAlD
Trimethoprim—ABCB1—lymph node—urinary bladder cancer	0.000108	0.00604	CbGeAlD
Trimethoprim—Neutropenia—Methotrexate—urinary bladder cancer	0.000107	0.00141	CcSEcCtD
Trimethoprim—Pruritus—Thiotepa—urinary bladder cancer	0.000107	0.00141	CcSEcCtD
Trimethoprim—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000106	0.0014	CcSEcCtD
Trimethoprim—Eosinophilia—Epirubicin—urinary bladder cancer	0.000106	0.0014	CcSEcCtD
Trimethoprim—Dyspnoea—Cisplatin—urinary bladder cancer	0.000105	0.00139	CcSEcCtD
Trimethoprim—Skin disorder—Etoposide—urinary bladder cancer	0.000105	0.00139	CcSEcCtD
Trimethoprim—Pancreatitis—Epirubicin—urinary bladder cancer	0.000105	0.00138	CcSEcCtD
Trimethoprim—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000104	0.00138	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000104	0.00138	CcSEcCtD
Trimethoprim—Anorexia—Etoposide—urinary bladder cancer	0.000103	0.00136	CcSEcCtD
Trimethoprim—Diarrhoea—Thiotepa—urinary bladder cancer	0.000103	0.00136	CcSEcCtD
Trimethoprim—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000103	0.00136	CcSEcCtD
Trimethoprim—Decreased appetite—Cisplatin—urinary bladder cancer	0.000103	0.00136	CcSEcCtD
Trimethoprim—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000103	0.00136	CcSEcCtD
Trimethoprim—Pneumonia—Methotrexate—urinary bladder cancer	0.000102	0.00135	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000102	0.00135	CcSEcCtD
Trimethoprim—Infestation—Methotrexate—urinary bladder cancer	0.000102	0.00134	CcSEcCtD
Trimethoprim—Infestation NOS—Methotrexate—urinary bladder cancer	0.000102	0.00134	CcSEcCtD
Trimethoprim—Depression—Methotrexate—urinary bladder cancer	0.000101	0.00134	CcSEcCtD
Trimethoprim—Pancytopenia—Epirubicin—urinary bladder cancer	0.000101	0.00134	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000101	0.00133	CcSEcCtD
Trimethoprim—Body temperature increased—Gemcitabine—urinary bladder cancer	0.0001	0.00132	CcSEcCtD
Trimethoprim—Renal failure—Methotrexate—urinary bladder cancer	0.0001	0.00132	CcSEcCtD
Trimethoprim—Neutropenia—Epirubicin—urinary bladder cancer	9.98e-05	0.00132	CcSEcCtD
Trimethoprim—Dizziness—Thiotepa—urinary bladder cancer	9.97e-05	0.00132	CcSEcCtD
Trimethoprim—Stomatitis—Methotrexate—urinary bladder cancer	9.91e-05	0.00131	CcSEcCtD
Trimethoprim—Urticaria—Fluorouracil—urinary bladder cancer	9.9e-05	0.00131	CcSEcCtD
Trimethoprim—Body temperature increased—Fluorouracil—urinary bladder cancer	9.86e-05	0.0013	CcSEcCtD
Trimethoprim—Eosinophilia—Doxorubicin—urinary bladder cancer	9.78e-05	0.00129	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Epirubicin—urinary bladder cancer	9.74e-05	0.00129	CcSEcCtD
Trimethoprim—Feeling abnormal—Cisplatin—urinary bladder cancer	9.74e-05	0.00129	CcSEcCtD
Trimethoprim—Haematuria—Methotrexate—urinary bladder cancer	9.7e-05	0.00128	CcSEcCtD
Trimethoprim—Pancreatitis—Doxorubicin—urinary bladder cancer	9.68e-05	0.00128	CcSEcCtD
Trimethoprim—Dyspnoea—Etoposide—urinary bladder cancer	9.65e-05	0.00128	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Methotrexate—urinary bladder cancer	9.62e-05	0.00127	CcSEcCtD
Trimethoprim—Epistaxis—Methotrexate—urinary bladder cancer	9.59e-05	0.00127	CcSEcCtD
Trimethoprim—Vomiting—Thiotepa—urinary bladder cancer	9.58e-05	0.00127	CcSEcCtD
Trimethoprim—Pneumonia—Epirubicin—urinary bladder cancer	9.57e-05	0.00127	CcSEcCtD
Trimethoprim—Infestation NOS—Epirubicin—urinary bladder cancer	9.52e-05	0.00126	CcSEcCtD
Trimethoprim—Infestation—Epirubicin—urinary bladder cancer	9.52e-05	0.00126	CcSEcCtD
Trimethoprim—Rash—Thiotepa—urinary bladder cancer	9.5e-05	0.00126	CcSEcCtD
Trimethoprim—Dermatitis—Thiotepa—urinary bladder cancer	9.5e-05	0.00125	CcSEcCtD
Trimethoprim—Agranulocytosis—Methotrexate—urinary bladder cancer	9.49e-05	0.00125	CcSEcCtD
Trimethoprim—Headache—Thiotepa—urinary bladder cancer	9.44e-05	0.00125	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	9.43e-05	0.00125	CcSEcCtD
Trimethoprim—Decreased appetite—Etoposide—urinary bladder cancer	9.41e-05	0.00124	CcSEcCtD
Trimethoprim—Pancytopenia—Doxorubicin—urinary bladder cancer	9.38e-05	0.00124	CcSEcCtD
Trimethoprim—Renal failure—Epirubicin—urinary bladder cancer	9.35e-05	0.00124	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Etoposide—urinary bladder cancer	9.35e-05	0.00124	CcSEcCtD
Trimethoprim—Body temperature increased—Cisplatin—urinary bladder cancer	9.34e-05	0.00123	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Epirubicin—urinary bladder cancer	9.33e-05	0.00123	CcSEcCtD
Trimethoprim—Stomatitis—Epirubicin—urinary bladder cancer	9.28e-05	0.00123	CcSEcCtD
Trimethoprim—Constipation—Etoposide—urinary bladder cancer	9.26e-05	0.00122	CcSEcCtD
Trimethoprim—Neutropenia—Doxorubicin—urinary bladder cancer	9.23e-05	0.00122	CcSEcCtD
Trimethoprim—Hypersensitivity—Fluorouracil—urinary bladder cancer	9.19e-05	0.00121	CcSEcCtD
Trimethoprim—Haematuria—Epirubicin—urinary bladder cancer	9.07e-05	0.0012	CcSEcCtD
Trimethoprim—Urinary tract disorder—Methotrexate—urinary bladder cancer	9.02e-05	0.00119	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	9.01e-05	0.00119	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Epirubicin—urinary bladder cancer	9e-05	0.00119	CcSEcCtD
Trimethoprim—Epistaxis—Epirubicin—urinary bladder cancer	8.98e-05	0.00119	CcSEcCtD
Trimethoprim—Pruritus—Gemcitabine—urinary bladder cancer	8.97e-05	0.00119	CcSEcCtD
Trimethoprim—Nausea—Thiotepa—urinary bladder cancer	8.95e-05	0.00118	CcSEcCtD
Trimethoprim—Urethral disorder—Methotrexate—urinary bladder cancer	8.95e-05	0.00118	CcSEcCtD
Trimethoprim—Feeling abnormal—Etoposide—urinary bladder cancer	8.92e-05	0.00118	CcSEcCtD
Trimethoprim—Agranulocytosis—Epirubicin—urinary bladder cancer	8.88e-05	0.00117	CcSEcCtD
Trimethoprim—Pneumonia—Doxorubicin—urinary bladder cancer	8.86e-05	0.00117	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Etoposide—urinary bladder cancer	8.85e-05	0.00117	CcSEcCtD
Trimethoprim—Pruritus—Fluorouracil—urinary bladder cancer	8.82e-05	0.00117	CcSEcCtD
Trimethoprim—Infestation NOS—Doxorubicin—urinary bladder cancer	8.81e-05	0.00116	CcSEcCtD
Trimethoprim—Infestation—Doxorubicin—urinary bladder cancer	8.81e-05	0.00116	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	8.73e-05	0.00115	CcSEcCtD
Trimethoprim—Hypersensitivity—Cisplatin—urinary bladder cancer	8.71e-05	0.00115	CcSEcCtD
Trimethoprim—Diarrhoea—Gemcitabine—urinary bladder cancer	8.68e-05	0.00115	CcSEcCtD
Trimethoprim—Renal failure—Doxorubicin—urinary bladder cancer	8.66e-05	0.00114	CcSEcCtD
Trimethoprim—Erythema multiforme—Methotrexate—urinary bladder cancer	8.63e-05	0.00114	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	8.63e-05	0.00114	CcSEcCtD
Trimethoprim—Urticaria—Etoposide—urinary bladder cancer	8.6e-05	0.00114	CcSEcCtD
Trimethoprim—Stomatitis—Doxorubicin—urinary bladder cancer	8.58e-05	0.00113	CcSEcCtD
Trimethoprim—Abdominal pain—Etoposide—urinary bladder cancer	8.56e-05	0.00113	CcSEcCtD
Trimethoprim—Body temperature increased—Etoposide—urinary bladder cancer	8.56e-05	0.00113	CcSEcCtD
Trimethoprim—Eye disorder—Methotrexate—urinary bladder cancer	8.53e-05	0.00113	CcSEcCtD
Trimethoprim—Diarrhoea—Fluorouracil—urinary bladder cancer	8.53e-05	0.00113	CcSEcCtD
Trimethoprim—Tinnitus—Methotrexate—urinary bladder cancer	8.51e-05	0.00112	CcSEcCtD
Trimethoprim—Urinary tract disorder—Epirubicin—urinary bladder cancer	8.44e-05	0.00112	CcSEcCtD
Trimethoprim—Haematuria—Doxorubicin—urinary bladder cancer	8.4e-05	0.00111	CcSEcCtD
Trimethoprim—Connective tissue disorder—Epirubicin—urinary bladder cancer	8.4e-05	0.00111	CcSEcCtD
Trimethoprim—Urethral disorder—Epirubicin—urinary bladder cancer	8.37e-05	0.00111	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	8.33e-05	0.0011	CcSEcCtD
Trimethoprim—Epistaxis—Doxorubicin—urinary bladder cancer	8.31e-05	0.0011	CcSEcCtD
Trimethoprim—Immune system disorder—Methotrexate—urinary bladder cancer	8.25e-05	0.00109	CcSEcCtD
Trimethoprim—Dizziness—Fluorouracil—urinary bladder cancer	8.24e-05	0.00109	CcSEcCtD
Trimethoprim—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.23e-05	0.00109	CcSEcCtD
Trimethoprim—Agranulocytosis—Doxorubicin—urinary bladder cancer	8.22e-05	0.00109	CcSEcCtD
Trimethoprim—Diarrhoea—Cisplatin—urinary bladder cancer	8.09e-05	0.00107	CcSEcCtD
Trimethoprim—Erythema multiforme—Epirubicin—urinary bladder cancer	8.08e-05	0.00107	CcSEcCtD
Trimethoprim—Vomiting—Gemcitabine—urinary bladder cancer	8.06e-05	0.00107	CcSEcCtD
Trimethoprim—Mental disorder—Methotrexate—urinary bladder cancer	8e-05	0.00106	CcSEcCtD
Trimethoprim—Rash—Gemcitabine—urinary bladder cancer	8e-05	0.00106	CcSEcCtD
Trimethoprim—Dermatitis—Gemcitabine—urinary bladder cancer	7.99e-05	0.00106	CcSEcCtD
Trimethoprim—Eye disorder—Epirubicin—urinary bladder cancer	7.98e-05	0.00106	CcSEcCtD
Trimethoprim—Hypersensitivity—Etoposide—urinary bladder cancer	7.98e-05	0.00105	CcSEcCtD
Trimethoprim—Tinnitus—Epirubicin—urinary bladder cancer	7.97e-05	0.00105	CcSEcCtD
Trimethoprim—Erythema—Methotrexate—urinary bladder cancer	7.95e-05	0.00105	CcSEcCtD
Trimethoprim—Malnutrition—Methotrexate—urinary bladder cancer	7.95e-05	0.00105	CcSEcCtD
Trimethoprim—Headache—Gemcitabine—urinary bladder cancer	7.94e-05	0.00105	CcSEcCtD
Trimethoprim—Vomiting—Fluorouracil—urinary bladder cancer	7.93e-05	0.00105	CcSEcCtD
Trimethoprim—Rash—Fluorouracil—urinary bladder cancer	7.86e-05	0.00104	CcSEcCtD
Trimethoprim—Dermatitis—Fluorouracil—urinary bladder cancer	7.85e-05	0.00104	CcSEcCtD
Trimethoprim—Headache—Fluorouracil—urinary bladder cancer	7.81e-05	0.00103	CcSEcCtD
Trimethoprim—Urinary tract disorder—Doxorubicin—urinary bladder cancer	7.81e-05	0.00103	CcSEcCtD
Trimethoprim—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.77e-05	0.00103	CcSEcCtD
Trimethoprim—Urethral disorder—Doxorubicin—urinary bladder cancer	7.75e-05	0.00102	CcSEcCtD
Trimethoprim—Immune system disorder—Epirubicin—urinary bladder cancer	7.72e-05	0.00102	CcSEcCtD
Trimethoprim—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.7e-05	0.00102	CcSEcCtD
Trimethoprim—Pruritus—Etoposide—urinary bladder cancer	7.66e-05	0.00101	CcSEcCtD
Trimethoprim—Nausea—Gemcitabine—urinary bladder cancer	7.53e-05	0.000995	CcSEcCtD
Trimethoprim—Vomiting—Cisplatin—urinary bladder cancer	7.51e-05	0.000993	CcSEcCtD
Trimethoprim—Mental disorder—Epirubicin—urinary bladder cancer	7.48e-05	0.000989	CcSEcCtD
Trimethoprim—Erythema multiforme—Doxorubicin—urinary bladder cancer	7.47e-05	0.000988	CcSEcCtD
Trimethoprim—Rash—Cisplatin—urinary bladder cancer	7.45e-05	0.000985	CcSEcCtD
Trimethoprim—Dermatitis—Cisplatin—urinary bladder cancer	7.45e-05	0.000984	CcSEcCtD
Trimethoprim—Erythema—Epirubicin—urinary bladder cancer	7.44e-05	0.000983	CcSEcCtD
Trimethoprim—Malnutrition—Epirubicin—urinary bladder cancer	7.44e-05	0.000983	CcSEcCtD
Trimethoprim—Diarrhoea—Etoposide—urinary bladder cancer	7.41e-05	0.000979	CcSEcCtD
Trimethoprim—Nausea—Fluorouracil—urinary bladder cancer	7.41e-05	0.000979	CcSEcCtD
Trimethoprim—Eye disorder—Doxorubicin—urinary bladder cancer	7.39e-05	0.000976	CcSEcCtD
Trimethoprim—Tinnitus—Doxorubicin—urinary bladder cancer	7.37e-05	0.000974	CcSEcCtD
Trimethoprim—Dizziness—Etoposide—urinary bladder cancer	7.16e-05	0.000946	CcSEcCtD
Trimethoprim—Immune system disorder—Doxorubicin—urinary bladder cancer	7.14e-05	0.000944	CcSEcCtD
Trimethoprim—Vertigo—Methotrexate—urinary bladder cancer	7.14e-05	0.000944	CcSEcCtD
Trimethoprim—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.12e-05	0.000942	CcSEcCtD
Trimethoprim—Leukopenia—Methotrexate—urinary bladder cancer	7.11e-05	0.00094	CcSEcCtD
Trimethoprim—Nausea—Cisplatin—urinary bladder cancer	7.02e-05	0.000928	CcSEcCtD
Trimethoprim—Cough—Methotrexate—urinary bladder cancer	6.93e-05	0.000916	CcSEcCtD
Trimethoprim—Mental disorder—Doxorubicin—urinary bladder cancer	6.93e-05	0.000915	CcSEcCtD
Trimethoprim—Convulsion—Methotrexate—urinary bladder cancer	6.89e-05	0.00091	CcSEcCtD
Trimethoprim—Vomiting—Etoposide—urinary bladder cancer	6.88e-05	0.00091	CcSEcCtD
Trimethoprim—Erythema—Doxorubicin—urinary bladder cancer	6.88e-05	0.000909	CcSEcCtD
Trimethoprim—Malnutrition—Doxorubicin—urinary bladder cancer	6.88e-05	0.000909	CcSEcCtD
Trimethoprim—Agitation—Epirubicin—urinary bladder cancer	6.83e-05	0.000903	CcSEcCtD
Trimethoprim—Rash—Etoposide—urinary bladder cancer	6.83e-05	0.000902	CcSEcCtD
Trimethoprim—Dermatitis—Etoposide—urinary bladder cancer	6.82e-05	0.000901	CcSEcCtD
Trimethoprim—Headache—Etoposide—urinary bladder cancer	6.78e-05	0.000896	CcSEcCtD
Trimethoprim—Arthralgia—Methotrexate—urinary bladder cancer	6.77e-05	0.000894	CcSEcCtD
Trimethoprim—Myalgia—Methotrexate—urinary bladder cancer	6.77e-05	0.000894	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.72e-05	0.000888	CcSEcCtD
Trimethoprim—Vertigo—Epirubicin—urinary bladder cancer	6.68e-05	0.000883	CcSEcCtD
Trimethoprim—Syncope—Epirubicin—urinary bladder cancer	6.67e-05	0.000881	CcSEcCtD
Trimethoprim—Leukopenia—Epirubicin—urinary bladder cancer	6.66e-05	0.00088	CcSEcCtD
Trimethoprim—Confusional state—Methotrexate—urinary bladder cancer	6.54e-05	0.000864	CcSEcCtD
Trimethoprim—Loss of consciousness—Epirubicin—urinary bladder cancer	6.54e-05	0.000864	CcSEcCtD
Trimethoprim—Cough—Epirubicin—urinary bladder cancer	6.49e-05	0.000858	CcSEcCtD
Trimethoprim—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.49e-05	0.000857	CcSEcCtD
Trimethoprim—Convulsion—Epirubicin—urinary bladder cancer	6.44e-05	0.000852	CcSEcCtD
Trimethoprim—Nausea—Etoposide—urinary bladder cancer	6.43e-05	0.00085	CcSEcCtD
Trimethoprim—Nervous system disorder—Methotrexate—urinary bladder cancer	6.36e-05	0.000841	CcSEcCtD
Trimethoprim—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.35e-05	0.000839	CcSEcCtD
Trimethoprim—Myalgia—Epirubicin—urinary bladder cancer	6.33e-05	0.000837	CcSEcCtD
Trimethoprim—Arthralgia—Epirubicin—urinary bladder cancer	6.33e-05	0.000837	CcSEcCtD
Trimethoprim—Agitation—Doxorubicin—urinary bladder cancer	6.32e-05	0.000836	CcSEcCtD
Trimethoprim—Anxiety—Epirubicin—urinary bladder cancer	6.31e-05	0.000834	CcSEcCtD
Trimethoprim—Skin disorder—Methotrexate—urinary bladder cancer	6.3e-05	0.000833	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.29e-05	0.000831	CcSEcCtD
Trimethoprim—Vertigo—Doxorubicin—urinary bladder cancer	6.18e-05	0.000817	CcSEcCtD
Trimethoprim—Anorexia—Methotrexate—urinary bladder cancer	6.18e-05	0.000817	CcSEcCtD
Trimethoprim—Syncope—Doxorubicin—urinary bladder cancer	6.17e-05	0.000816	CcSEcCtD
Trimethoprim—Leukopenia—Doxorubicin—urinary bladder cancer	6.16e-05	0.000814	CcSEcCtD
Trimethoprim—Confusional state—Epirubicin—urinary bladder cancer	6.12e-05	0.000809	CcSEcCtD
Trimethoprim—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.07e-05	0.000802	CcSEcCtD
Trimethoprim—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.05e-05	0.000799	CcSEcCtD
Trimethoprim—Cough—Doxorubicin—urinary bladder cancer	6e-05	0.000794	CcSEcCtD
Trimethoprim—Shock—Epirubicin—urinary bladder cancer	5.97e-05	0.000789	CcSEcCtD
Trimethoprim—Convulsion—Doxorubicin—urinary bladder cancer	5.96e-05	0.000788	CcSEcCtD
Trimethoprim—Nervous system disorder—Epirubicin—urinary bladder cancer	5.95e-05	0.000787	CcSEcCtD
Trimethoprim—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.94e-05	0.000785	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.91e-05	0.000781	CcSEcCtD
Trimethoprim—Skin disorder—Epirubicin—urinary bladder cancer	5.9e-05	0.000779	CcSEcCtD
Trimethoprim—Insomnia—Methotrexate—urinary bladder cancer	5.87e-05	0.000775	CcSEcCtD
Trimethoprim—Myalgia—Doxorubicin—urinary bladder cancer	5.86e-05	0.000774	CcSEcCtD
Trimethoprim—Arthralgia—Doxorubicin—urinary bladder cancer	5.86e-05	0.000774	CcSEcCtD
Trimethoprim—Anxiety—Doxorubicin—urinary bladder cancer	5.84e-05	0.000772	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.82e-05	0.000769	CcSEcCtD
Trimethoprim—Anorexia—Epirubicin—urinary bladder cancer	5.79e-05	0.000765	CcSEcCtD
Trimethoprim—Dyspnoea—Methotrexate—urinary bladder cancer	5.78e-05	0.000764	CcSEcCtD
Trimethoprim—Dyspepsia—Methotrexate—urinary bladder cancer	5.71e-05	0.000755	CcSEcCtD
Trimethoprim—Confusional state—Doxorubicin—urinary bladder cancer	5.66e-05	0.000748	CcSEcCtD
Trimethoprim—Decreased appetite—Methotrexate—urinary bladder cancer	5.64e-05	0.000745	CcSEcCtD
Trimethoprim—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.62e-05	0.000742	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.6e-05	0.00074	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.53e-05	0.000731	CcSEcCtD
Trimethoprim—Shock—Doxorubicin—urinary bladder cancer	5.53e-05	0.00073	CcSEcCtD
Trimethoprim—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.51e-05	0.000728	CcSEcCtD
Trimethoprim—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.5e-05	0.000727	CcSEcCtD
Trimethoprim—Insomnia—Epirubicin—urinary bladder cancer	5.49e-05	0.000726	CcSEcCtD
Trimethoprim—Skin disorder—Doxorubicin—urinary bladder cancer	5.45e-05	0.000721	CcSEcCtD
Trimethoprim—Dyspnoea—Epirubicin—urinary bladder cancer	5.41e-05	0.000715	CcSEcCtD
Trimethoprim—Anorexia—Doxorubicin—urinary bladder cancer	5.35e-05	0.000707	CcSEcCtD
Trimethoprim—Feeling abnormal—Methotrexate—urinary bladder cancer	5.34e-05	0.000706	CcSEcCtD
Trimethoprim—Dyspepsia—Epirubicin—urinary bladder cancer	5.34e-05	0.000706	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.3e-05	0.000701	CcSEcCtD
Trimethoprim—Decreased appetite—Epirubicin—urinary bladder cancer	5.28e-05	0.000697	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.24e-05	0.000693	CcSEcCtD
Trimethoprim—Constipation—Epirubicin—urinary bladder cancer	5.19e-05	0.000686	CcSEcCtD
Trimethoprim—Urticaria—Methotrexate—urinary bladder cancer	5.15e-05	0.000681	CcSEcCtD
Trimethoprim—Abdominal pain—Methotrexate—urinary bladder cancer	5.13e-05	0.000678	CcSEcCtD
Trimethoprim—Body temperature increased—Methotrexate—urinary bladder cancer	5.13e-05	0.000678	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.12e-05	0.000676	CcSEcCtD
Trimethoprim—Insomnia—Doxorubicin—urinary bladder cancer	5.08e-05	0.000671	CcSEcCtD
Trimethoprim—Dyspnoea—Doxorubicin—urinary bladder cancer	5.01e-05	0.000662	CcSEcCtD
Trimethoprim—Feeling abnormal—Epirubicin—urinary bladder cancer	5e-05	0.000661	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.96e-05	0.000656	CcSEcCtD
Trimethoprim—Dyspepsia—Doxorubicin—urinary bladder cancer	4.94e-05	0.000653	CcSEcCtD
Trimethoprim—Decreased appetite—Doxorubicin—urinary bladder cancer	4.88e-05	0.000645	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.85e-05	0.000641	CcSEcCtD
Trimethoprim—Urticaria—Epirubicin—urinary bladder cancer	4.82e-05	0.000637	CcSEcCtD
Trimethoprim—Constipation—Doxorubicin—urinary bladder cancer	4.8e-05	0.000635	CcSEcCtD
Trimethoprim—Abdominal pain—Epirubicin—urinary bladder cancer	4.8e-05	0.000634	CcSEcCtD
Trimethoprim—Body temperature increased—Epirubicin—urinary bladder cancer	4.8e-05	0.000634	CcSEcCtD
Trimethoprim—Hypersensitivity—Methotrexate—urinary bladder cancer	4.78e-05	0.000632	CcSEcCtD
Trimethoprim—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.63e-05	0.000612	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.59e-05	0.000607	CcSEcCtD
Trimethoprim—Pruritus—Methotrexate—urinary bladder cancer	4.59e-05	0.000606	CcSEcCtD
Trimethoprim—Hypersensitivity—Epirubicin—urinary bladder cancer	4.47e-05	0.000591	CcSEcCtD
Trimethoprim—Urticaria—Doxorubicin—urinary bladder cancer	4.46e-05	0.00059	CcSEcCtD
Trimethoprim—Body temperature increased—Doxorubicin—urinary bladder cancer	4.44e-05	0.000587	CcSEcCtD
Trimethoprim—Abdominal pain—Doxorubicin—urinary bladder cancer	4.44e-05	0.000587	CcSEcCtD
Trimethoprim—Diarrhoea—Methotrexate—urinary bladder cancer	4.44e-05	0.000586	CcSEcCtD
Trimethoprim—Pruritus—Epirubicin—urinary bladder cancer	4.29e-05	0.000568	CcSEcCtD
Trimethoprim—Dizziness—Methotrexate—urinary bladder cancer	4.29e-05	0.000567	CcSEcCtD
Trimethoprim—Diarrhoea—Epirubicin—urinary bladder cancer	4.15e-05	0.000549	CcSEcCtD
Trimethoprim—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.14e-05	0.000547	CcSEcCtD
Trimethoprim—Vomiting—Methotrexate—urinary bladder cancer	4.12e-05	0.000545	CcSEcCtD
Trimethoprim—Rash—Methotrexate—urinary bladder cancer	4.09e-05	0.00054	CcSEcCtD
Trimethoprim—Dermatitis—Methotrexate—urinary bladder cancer	4.09e-05	0.00054	CcSEcCtD
Trimethoprim—Headache—Methotrexate—urinary bladder cancer	4.06e-05	0.000537	CcSEcCtD
Trimethoprim—Dizziness—Epirubicin—urinary bladder cancer	4.01e-05	0.00053	CcSEcCtD
Trimethoprim—Pruritus—Doxorubicin—urinary bladder cancer	3.97e-05	0.000525	CcSEcCtD
Trimethoprim—Vomiting—Epirubicin—urinary bladder cancer	3.86e-05	0.00051	CcSEcCtD
Trimethoprim—Nausea—Methotrexate—urinary bladder cancer	3.85e-05	0.000509	CcSEcCtD
Trimethoprim—Diarrhoea—Doxorubicin—urinary bladder cancer	3.84e-05	0.000508	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—CDK4—urinary bladder cancer	3.84e-05	0.000554	CbGpPWpGaD
Trimethoprim—DHFR—Disease—RBX1—urinary bladder cancer	3.83e-05	0.000553	CbGpPWpGaD
Trimethoprim—Rash—Epirubicin—urinary bladder cancer	3.83e-05	0.000506	CcSEcCtD
Trimethoprim—Dermatitis—Epirubicin—urinary bladder cancer	3.82e-05	0.000505	CcSEcCtD
Trimethoprim—Headache—Epirubicin—urinary bladder cancer	3.8e-05	0.000503	CcSEcCtD
Trimethoprim—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	3.78e-05	0.000545	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	3.75e-05	0.000541	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—TERT—urinary bladder cancer	3.74e-05	0.00054	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.73e-05	0.000539	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—RB1—urinary bladder cancer	3.73e-05	0.000539	CbGpPWpGaD
Trimethoprim—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.73e-05	0.000538	CbGpPWpGaD
Trimethoprim—Dizziness—Doxorubicin—urinary bladder cancer	3.71e-05	0.000491	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.7e-05	0.000534	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—NAT2—urinary bladder cancer	3.69e-05	0.000533	CbGpPWpGaD
Trimethoprim—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.67e-05	0.00053	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—RRM2—urinary bladder cancer	3.65e-05	0.000527	CbGpPWpGaD
Trimethoprim—Nausea—Epirubicin—urinary bladder cancer	3.61e-05	0.000476	CcSEcCtD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.59e-05	0.000519	CbGpPWpGaD
Trimethoprim—Vomiting—Doxorubicin—urinary bladder cancer	3.57e-05	0.000472	CcSEcCtD
Trimethoprim—Rash—Doxorubicin—urinary bladder cancer	3.54e-05	0.000468	CcSEcCtD
Trimethoprim—Dermatitis—Doxorubicin—urinary bladder cancer	3.54e-05	0.000468	CcSEcCtD
Trimethoprim—Headache—Doxorubicin—urinary bladder cancer	3.52e-05	0.000465	CcSEcCtD
Trimethoprim—DHFR—Disease—JAG1—urinary bladder cancer	3.43e-05	0.000495	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—ENO2—urinary bladder cancer	3.38e-05	0.000488	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—HPGDS—urinary bladder cancer	3.38e-05	0.000488	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—ATM—urinary bladder cancer	3.36e-05	0.000485	CbGpPWpGaD
Trimethoprim—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.35e-05	0.000484	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—CDK4—urinary bladder cancer	3.35e-05	0.000483	CbGpPWpGaD
Trimethoprim—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	3.35e-05	0.000483	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—RB1—urinary bladder cancer	3.34e-05	0.000482	CbGpPWpGaD
Trimethoprim—Nausea—Doxorubicin—urinary bladder cancer	3.34e-05	0.000441	CcSEcCtD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.32e-05	0.000479	CbGpPWpGaD
Trimethoprim—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.3e-05	0.000476	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.29e-05	0.000475	CbGpPWpGaD
Trimethoprim—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	3.28e-05	0.000474	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—GSTT1—urinary bladder cancer	3.28e-05	0.000474	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	3.28e-05	0.000474	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—RB1—urinary bladder cancer	3.26e-05	0.00047	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.21e-05	0.000463	CbGpPWpGaD
Trimethoprim—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.21e-05	0.000463	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—RRM2—urinary bladder cancer	3.19e-05	0.00046	CbGpPWpGaD
Trimethoprim—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	3.18e-05	0.000459	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—TP53—urinary bladder cancer	3.16e-05	0.000456	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.12e-05	0.00045	CbGpPWpGaD
Trimethoprim—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	3.08e-05	0.000444	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.06e-05	0.000442	CbGpPWpGaD
Trimethoprim—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.03e-05	0.000438	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—ENO2—urinary bladder cancer	2.95e-05	0.000426	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—HPGDS—urinary bladder cancer	2.95e-05	0.000426	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—CDKN2A—urinary bladder cancer	2.93e-05	0.000423	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—RB1—urinary bladder cancer	2.91e-05	0.00042	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—GSTT1—urinary bladder cancer	2.86e-05	0.000413	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	2.86e-05	0.000413	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	2.77e-05	0.0004	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—NQO1—urinary bladder cancer	2.73e-05	0.000394	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.71e-05	0.000392	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	2.68e-05	0.000387	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.62e-05	0.000378	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—CDKN2A—urinary bladder cancer	2.56e-05	0.000369	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—EP300—urinary bladder cancer	2.55e-05	0.000368	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	2.52e-05	0.000363	CbGpPWpGaD
Trimethoprim—DHFR—Disease—NCOR1—urinary bladder cancer	2.5e-05	0.00036	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—CCND1—urinary bladder cancer	2.48e-05	0.000358	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	2.42e-05	0.000349	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—CDKN1A—urinary bladder cancer	2.4e-05	0.000346	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.4e-05	0.000346	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.39e-05	0.000345	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	2.39e-05	0.000345	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NAT1—urinary bladder cancer	2.39e-05	0.000345	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—NQO1—urinary bladder cancer	2.38e-05	0.000344	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.38e-05	0.000343	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.35e-05	0.000339	CbGpPWpGaD
Trimethoprim—DHFR—Disease—ERCC2—urinary bladder cancer	2.35e-05	0.000339	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	2.34e-05	0.000338	CbGpPWpGaD
Trimethoprim—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.33e-05	0.000337	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—EP300—urinary bladder cancer	2.28e-05	0.000329	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—GSTP1—urinary bladder cancer	2.28e-05	0.000328	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—EP300—urinary bladder cancer	2.23e-05	0.000321	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.22e-05	0.000321	CbGpPWpGaD
Trimethoprim—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.21e-05	0.000318	CbGpPWpGaD
Trimethoprim—DHFR—Disease—MTHFR—urinary bladder cancer	2.21e-05	0.000318	CbGpPWpGaD
Trimethoprim—DHFR—Disease—TERT—urinary bladder cancer	2.2e-05	0.000318	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.19e-05	0.000317	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	2.18e-05	0.000315	CbGpPWpGaD
Trimethoprim—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.18e-05	0.000314	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—CCND1—urinary bladder cancer	2.16e-05	0.000312	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—TYMS—urinary bladder cancer	2.12e-05	0.000305	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—CDKN1A—urinary bladder cancer	2.09e-05	0.000302	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—GSTM1—urinary bladder cancer	2.09e-05	0.000302	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—NCOR1—urinary bladder cancer	2.09e-05	0.000302	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.08e-05	0.000301	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.08e-05	0.0003	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.08e-05	0.0003	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.06e-05	0.000297	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.05e-05	0.000296	CbGpPWpGaD
Trimethoprim—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.03e-05	0.000293	CbGpPWpGaD
Trimethoprim—DHFR—Disease—FGFR3—urinary bladder cancer	2.02e-05	0.000291	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—GPX1—urinary bladder cancer	2e-05	0.000289	CbGpPWpGaD
Trimethoprim—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2e-05	0.000289	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—EP300—urinary bladder cancer	1.99e-05	0.000287	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—MYC—urinary bladder cancer	1.99e-05	0.000287	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—GSTP1—urinary bladder cancer	1.99e-05	0.000287	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	1.97e-05	0.000284	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—ERCC2—urinary bladder cancer	1.97e-05	0.000284	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.94e-05	0.00028	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.94e-05	0.00028	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.94e-05	0.00028	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.91e-05	0.000276	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.9e-05	0.000275	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	1.86e-05	0.000268	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—MTHFR—urinary bladder cancer	1.85e-05	0.000267	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—GSTM1—urinary bladder cancer	1.82e-05	0.000263	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—NCOR1—urinary bladder cancer	1.82e-05	0.000263	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	1.81e-05	0.000261	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.78e-05	0.000256	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.77e-05	0.000255	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—GPX1—urinary bladder cancer	1.75e-05	0.000252	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.75e-05	0.000252	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—MYC—urinary bladder cancer	1.74e-05	0.00025	CbGpPWpGaD
Trimethoprim—DHFR—Disease—CREBBP—urinary bladder cancer	1.72e-05	0.000248	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—ERCC2—urinary bladder cancer	1.72e-05	0.000248	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.71e-05	0.000247	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.71e-05	0.000246	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—TP53—urinary bladder cancer	1.63e-05	0.000236	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.62e-05	0.000233	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—MTHFR—urinary bladder cancer	1.61e-05	0.000233	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.6e-05	0.000231	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.58e-05	0.000228	CbGpPWpGaD
Trimethoprim—DHFR—Disease—RHOA—urinary bladder cancer	1.56e-05	0.000224	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.54e-05	0.000223	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.51e-05	0.000218	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PPARG—urinary bladder cancer	1.5e-05	0.000216	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.49e-05	0.000215	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.49e-05	0.000215	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.47e-05	0.000213	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.45e-05	0.000209	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.45e-05	0.000209	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—CREBBP—urinary bladder cancer	1.44e-05	0.000208	CbGpPWpGaD
Trimethoprim—DHFR—Disease—ERBB2—urinary bladder cancer	1.44e-05	0.000208	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—TP53—urinary bladder cancer	1.43e-05	0.000206	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.42e-05	0.000205	CbGpPWpGaD
Trimethoprim—DHFR—Disease—PTGS2—urinary bladder cancer	1.41e-05	0.000203	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.39e-05	0.000201	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.38e-05	0.000199	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.35e-05	0.000195	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.31e-05	0.000189	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PPARG—urinary bladder cancer	1.31e-05	0.000189	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.28e-05	0.000185	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.28e-05	0.000185	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.26e-05	0.000182	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—CREBBP—urinary bladder cancer	1.26e-05	0.000181	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.24e-05	0.000178	CbGpPWpGaD
Trimethoprim—DHFR—Disease—CDKN1A—urinary bladder cancer	1.23e-05	0.000178	CbGpPWpGaD
Trimethoprim—DHFR—Disease—PTEN—urinary bladder cancer	1.23e-05	0.000177	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.21e-05	0.000175	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.18e-05	0.00017	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PTGS2—urinary bladder cancer	1.18e-05	0.00017	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.18e-05	0.00017	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.17e-05	0.000169	CbGpPWpGaD
Trimethoprim—DHFR—Disease—EP300—urinary bladder cancer	1.17e-05	0.000169	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.15e-05	0.000166	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.14e-05	0.000165	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.14e-05	0.000164	CbGpPWpGaD
Trimethoprim—DHFR—Disease—SRC—urinary bladder cancer	1.14e-05	0.000164	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.13e-05	0.000163	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.13e-05	0.000163	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.06e-05	0.000154	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.06e-05	0.000152	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.05e-05	0.000151	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.05e-05	0.000151	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.04e-05	0.00015	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	0.000148	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PTEN—urinary bladder cancer	1.03e-05	0.000148	CbGpPWpGaD
Trimethoprim—DHFR—Disease—MYC—urinary bladder cancer	1.02e-05	0.000147	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.02e-05	0.000147	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.01e-05	0.000146	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.99e-06	0.000144	CbGpPWpGaD
Trimethoprim—DHFR—Disease—EGFR—urinary bladder cancer	9.98e-06	0.000144	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	9.97e-06	0.000144	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—RRM2—urinary bladder cancer	9.84e-06	0.000142	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—EP300—urinary bladder cancer	9.8e-06	0.000141	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	9.71e-06	0.00014	CbGpPWpGaD
Trimethoprim—DHFR—Disease—KRAS—urinary bladder cancer	9.43e-06	0.000136	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—RRM2—urinary bladder cancer	9.19e-06	0.000133	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—HPGDS—urinary bladder cancer	9.11e-06	0.000131	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—ENO2—urinary bladder cancer	9.11e-06	0.000131	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PTEN—urinary bladder cancer	8.97e-06	0.000129	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GSTT1—urinary bladder cancer	8.84e-06	0.000128	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—EP300—urinary bladder cancer	8.56e-06	0.000123	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—ENO2—urinary bladder cancer	8.51e-06	0.000123	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	8.51e-06	0.000123	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.46e-06	0.000122	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NQO1—urinary bladder cancer	8.43e-06	0.000122	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.28e-06	0.000119	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	8.26e-06	0.000119	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.18e-06	0.000118	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.13e-06	0.000117	CbGpPWpGaD
Trimethoprim—DHFR—Disease—HRAS—urinary bladder cancer	8.01e-06	0.000116	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—TYMP—urinary bladder cancer	7.77e-06	0.000112	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NQO1—urinary bladder cancer	7.35e-06	0.000106	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.13e-06	0.000103	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	7.03e-06	0.000101	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NAT2—urinary bladder cancer	7.02e-06	0.000101	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NQO1—urinary bladder cancer	6.86e-06	9.9e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.8e-06	9.82e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.66e-06	9.61e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—TYMS—urinary bladder cancer	6.54e-06	9.43e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	6.46e-06	9.32e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	6.46e-06	9.32e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GPX1—urinary bladder cancer	6.19e-06	8.93e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.13e-06	8.84e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	6.08e-06	8.77e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.06e-06	8.75e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.81e-06	8.38e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.72e-06	8.26e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	5.71e-06	8.24e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.7e-06	8.22e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.63e-06	8.12e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.63e-06	8.12e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.61e-06	8.1e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.61e-06	8.1e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.54e-06	7.99e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.45e-06	7.86e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.39e-06	7.78e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—TYMS—urinary bladder cancer	5.32e-06	7.68e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.29e-06	7.64e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	5.26e-06	7.59e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	5.26e-06	7.59e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.04e-06	7.27e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.98e-06	7.18e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.95e-06	7.14e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.65e-06	6.71e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PPARG—urinary bladder cancer	4.63e-06	6.68e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.53e-06	6.53e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	4.45e-06	6.42e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.03e-06	5.82e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.88e-06	5.59e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.77e-06	5.45e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.77e-06	5.44e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.64e-06	5.26e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.62e-06	5.22e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.51e-06	5.06e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.47e-06	5.01e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.47e-06	5.01e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.32e-06	4.79e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.26e-06	4.71e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PTEN—urinary bladder cancer	3.18e-06	4.58e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.17e-06	4.58e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.07e-06	4.42e-05	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.03e-06	4.37e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.97e-06	4.28e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.77e-06	3.99e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—EP300—urinary bladder cancer	2.64e-06	3.81e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.59e-06	3.73e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.49e-06	3.59e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.47e-06	3.56e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.39e-06	3.45e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.96e-06	2.82e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.71e-06	2.46e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.63e-06	2.35e-05	CbGpPWpGaD
